文献速递肥胖与代谢综合征糖尿病

康复期SARS-CoV-2 IgG与中和抗体在代谢健康欠佳个体中升高

Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

这项回顾性研究纳入纽约长老会/威尔康奈尔医院新冠康复期门诊患者,分析SARS-CoV-2 IgG与代谢综合征合并症的关系。结果显示,合并肥胖等代谢综合征者康复期IgG水平显著更高,且IgG与BMI正相关,BMI≥30者中和抗体滴度更高。

要点

  • 康复期SARS-CoV-2 IgG水平在合并代谢综合征合并症者中显著更高。
  • 调整年龄、性别、种族和症状至检测时间后,IgG升高仍与肥胖显著相关。
  • BMI与抗体水平正相关,BMI≥30者中和抗体滴度更高。

核心结论

  • 康复期SARS-CoV-2 IgG和中和抗体在肥胖患者中升高,BMI与抗体水平呈正相关。

研究设计与样本

  • 回顾性研究,纳入2020年4月17日至5月20日SARS-CoV-2血清学阳性的成人康复期门诊患者进行描述与相关性分析。
  • 第二队列(2020年5月21日至6月21日)额外收集SARS-CoV-2 IgG、BMI、HbA1c和血脂数据,并在部分研究队列中检测中和抗体。

主要发现

  • 合并代谢综合征合并症的康复期个体SARS-CoV-2 IgG水平显著更高。
  • 调整年龄、性别、种族和症状至检测时间后,IgG升高仍与肥胖显著相关(P < 0.0001)。
  • HbA1c ≥6.5%者SARS-CoV-2 IgG水平显著高于HbA1c <5.7%者(P = 0.0197),多变量分析仍显著(P = 0.0104)。
  • BMI与抗体水平呈正相关[95%CI: 0.37 (0.20-0.52),P < 0.0001]。
  • BMI ≥ 30的COVID-19个体中和抗体滴度更高(P = 0.0055)。

关键数值与推荐

  • 肥胖与康复期SARS-CoV-2 IgG升高独立相关(P < 0.0001)。
  • HbA1c ≥6.5% vs <5.7%者IgG水平差异P = 0.0197,多变量分析P = 0.0104。
  • BMI与抗体水平相关系数0.37(95%CI 0.20-0.52),P < 0.0001。
  • BMI ≥ 30者中和抗体滴度更高,P = 0.0055。

临床怎么用

  • 对有代谢综合征合并症(尤其肥胖)的新冠康复者,应关注其抗体水平可能较高。
  • BMI与康复期抗体水平正相关,提示代谢健康状态可能影响体液免疫应答。
  • HbA1c≥6.5%者康复期IgG更高,提示血糖控制欠佳者抗体反应可能不同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Comorbidities making up metabolic syndrome (MetS), such as obesity, type 2 diabetes, and chronic cardiovascular disease can lead to increased risk of coronavirus disease-2019 (COVID-19) with a higher morbidity and mortality. SARS-CoV-2 antibodies are higher in severely or critically ill COVID-19 patients, but studies have not focused on levels in convalescent patients with MetS, which this study aimed to assess. METHODS: This retrospective study focused on adult convalescent outpatients with SARS-CoV-2 positive serology during the COVID-19 pandemic at NewYork Presbyterian/Weill Cornell. Data collected for descriptive and correlative analysis included SARS-COV-2 immunoglobin G (IgG) levels and history of MetS comorbidities from April 17, 2020 to May 20, 2020. Additional data, including SARS-CoV-2 IgG levels, body mass index (BMI), hemoglobin A1c (HbA1c) and lipid levels were collected and analyzed for a second cohort from May 21, 2020 to June 21, 2020. SARS-CoV-2 neutralizing antibodies were measured in a subset of the study cohort. RESULTS: SARS-CoV-2 IgG levels were significantly higher in convalescent individuals with MetS comorbidities. When adjusted for age, sex, race, and time duration from symptom onset to testing, increased SARS-CoV-2 IgG levels remained significantly associated with obesity (P < 0.0001). SARS-CoV-2 IgG levels were significantly higher in patients with HbA1c ≥6.5% compared to those with HbA1c <5.7% (P = 0.0197) and remained significant on multivariable analysis (P = 0.0104). A positive correlation was noted between BMI and antibody levels [95% confidence interval: 0.37 (0.20-0.52) P < 0.0001]. Neutralizing antibody titers were higher in COVID-19 individuals with BMI ≥ 30 (P = 0.0055). CONCLUSION: Postconvalescent SARS-CoV-2 IgG and neutralizing antibodies are elevated in obese patients, and a positive correlation exists between BMI and antibody levels.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Racine-Brzostek SE, Yang HS, Jack GA, et al. Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health. J Clin Endocrinol Metab. 2021. PMID: 33524125. doi:10.1210/clinem/dgab004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。